

Table 1.21
U.S. Prevalence Counts, Invasive Cancers Only, January 1, 2008^a
Using Different Tumor Inclusion Criteria^b

Site	Sex	5-Year Limited Duration			33-year Limited Duration	
		1st Invasive Tumor Ever ^c	1st Per Site in Previous 33 Years ^d	1st Per Site in Previous 5 Years ^e	1st Invasive Tumor Ever ^c	1st Per Site in Previous 33 Years ^d
All Sites	Both Sexes	4,249,706	4,331,842	4,734,286	11,688,972	11,892,768
	Male	2,188,126	2,219,768	2,413,895	5,506,074	5,570,768
	Female	2,061,580	2,112,074	2,320,391	6,182,898	6,322,000
Oral Cavity & Pharynx	Both Sexes	94,344	107,847	111,563	245,098	269,441
	Male	65,141	73,776	76,117	159,807	174,074
	Female	29,203	34,071	35,446	85,291	95,367
Esophagus	Both Sexes	19,829	23,939	23,951	30,597	35,817
	Male	15,229	18,405	18,417	23,362	27,236
	Female	4,600	5,534	5,534	7,235	8,581
Stomach	Both Sexes	33,089	39,300	39,521	65,498	74,863
	Male	19,927	23,973	24,073	37,436	43,123
	Female	13,162	15,327	15,448	28,062	31,740
Colon & Rectum	Both Sexes	407,014	469,977	478,669	1,098,089	1,223,141
	Male	205,716	237,703	241,917	540,332	598,652
	Female	201,298	232,274	236,752	557,757	624,489
Liver & Intrahepatic Bile Duct	Both Sexes	23,568	26,629	26,633	31,341	34,942
	Male	17,221	19,339	19,343	21,890	24,282
	Female	6,347	7,290	7,290	9,451	10,660
Pancreas	Both Sexes	26,137	31,728	31,739	34,955	41,506
	Male	12,950	15,750	15,761	16,972	20,161
	Female	13,187	15,978	15,978	17,983	21,345
Larynx	Both Sexes	30,287	36,587	36,906	87,991	98,455
	Male	24,152	29,051	29,312	70,449	78,408
	Female	6,135	7,536	7,594	17,542	20,047
Lung & Bronchus	Both Sexes	220,060	276,893	283,557	371,171	450,808
	Male	103,405	130,714	133,454	171,338	207,978
	Female	116,655	146,179	150,103	199,833	242,830
Melanoma of the Skin	Both Sexes	252,206	283,584	294,513	796,296	855,750
	Male	133,991	153,602	160,698	394,107	428,125
	Female	118,215	129,982	133,815	402,189	427,625
Breast	Female	805,515	868,236	918,683	2,606,497	2,763,127
Cervix	Female	38,294	40,160	40,257	200,357	206,078
Corpus & Uterus, NOS	Female	154,529	174,300	174,371	541,737	589,947
Ovary ^f	Female	54,970	63,837	63,889	161,711	181,687

^a U.S. 2008 cancer prevalence counts are based on 2008 cancer prevalence proportions from the SEER 9 registries and 1/1/2008 U.S. population estimates based on the average of 2007 and 2008 population estimates from the U.S. Bureau of the Census.

^b Prevalence estimates are ambiguous for those with multiple cancers, unless the tumor inclusion criteria are understood. Depending on the application, different inclusion criteria may be appropriate. This table provides three different methods of tumor inclusion:

^c (c) First invasive tumor ever
^d (d) First invasive tumor for each cancer site diagnosed during the previous 33 years (1975-2007)
^e (e) First invasive tumor for each cancer site diagnosed during the previous 5 years (2003-2007)
For definitions (d) and (e) all sites is treated as a separate cancer "site".

Consider a woman who had three invasive cancers: Melanoma in 1981; Breast cancer in 2003; Melanoma in 2004.
In method (c) the melanoma is the woman's first cancer, and is counted for the melanoma and all sites 33-year limited duration prevalence. For 5-year limited duration prevalence, the woman is not counted at all since her first cancer occurred more than 5 years prior to 1/1/2008.
In method (d) the 1981 melanoma is counted for the melanoma and all sites 33-year limited duration prevalence. The 2003 breast cancer is counted for the breast 5-year and 33-year limited duration prevalence.
In method (e) the 2003 breast cancer is counted for the breast cancer and all sites 5-year limited duration prevalence. The 2004 melanoma is counted for 5-year limited duration prevalence for melanoma.

^f Ovary excludes borderline cases or histologies 8442, 8451, 8462, 8472, and 8473.

Table 1.21 - continued
U.S. Prevalence Counts, Invasive Cancers Only, January 1, 2008^a
Using Different Tumor Inclusion Criteria^b

Site	Sex	5-Year Limited Duration			33-year Limited Duration	
		1st Invasive Tumor Ever ^c	1st Per Site in Previous 33 Years ^d	1st Per Site in Previous 5 Years ^e	1st Invasive Tumor Ever ^c	1st Per Site in Previous 33 Years ^d
Prostate	Male	970,359	1,048,069	1,048,105	2,396,871	2,555,936
Testis	Male	40,125	40,828	41,397	187,670	190,120
Urinary Bladder	Both Sexes	194,097	239,746	244,623	531,166	614,655
	Male	146,585	181,724	185,560	395,025	456,695
	Female	47,512	58,022	59,063	136,141	157,960
Kidney & Renal Pelvis	Both Sexes	128,486	155,791	157,332	290,688	337,899
	Male	77,495	95,049	96,135	171,540	201,021
	Female	50,991	60,742	61,197	119,148	136,878
Brain & Nervous System	Both Sexes	40,898	43,394	43,831	116,955	120,623
	Male	22,693	24,140	24,351	62,642	64,690
	Female	18,205	19,254	19,480	54,313	55,933
Thyroid	Both Sexes	139,961	153,689	154,081	425,181	450,805
	Male	31,088	35,530	35,602	93,227	100,569
	Female	108,873	118,159	118,479	331,954	350,236
Hodgkin Lymphoma	Both Sexes	36,835	39,099	39,099	155,837	159,846
	Male	19,688	20,808	20,808	80,709	82,717
	Female	17,147	18,291	18,291	75,128	77,129
Non-Hodgkin Lymphoma	Both Sexes	189,410	220,661	222,116	452,242	502,943
	Male	98,768	116,412	117,193	234,240	260,923
	Female	90,642	104,249	104,923	218,002	242,020
Myeloma	Both Sexes	42,726	49,682	49,741	65,682	74,814
	Male	23,046	27,105	27,164	36,054	41,454
	Female	19,680	22,577	22,577	29,628	33,360
Leukemia	Both Sexes	103,646	117,597	117,772	252,119	274,930
	Male	59,538	68,094	68,189	142,621	155,942
	Female	44,108	49,503	49,583	109,498	118,988
Acute Lymphocytic Leukemia	Both Sexes	15,402	15,740	15,740	59,985	60,486
	Male	8,796	8,940	8,940	33,127	33,297
	Female	6,606	6,800	6,800	26,858	27,189
Childhood (Ages 0-19)	Both Sexes	59,739	59,851	60,342	277,294	277,798
	Male	31,980	32,036	32,261	142,787	143,010
	Female	27,759	27,815	28,081	134,507	134,788
Kaposi Sarcoma	Both Sexes	6,661	7,109	7,109	22,566	23,720
	Male	6,221	6,561	6,561	21,226	22,190
	Female	440	548	548	1,340	1,530
Mesothelioma	Both Sexes	3,148	3,988	3,988	4,609	5,619
	Male	2,120	2,735	2,735	2,681	3,419
	Female	1,028	1,253	1,253	1,928	2,200

^a U.S. 2008 cancer prevalence counts are based on 2008 cancer prevalence proportions from the SEER 9 registries and 1/1/2008 U.S. population estimates based on the average of 2007 and 2008 population estimates from the U.S. Bureau of the Census.

^b Prevalence estimates are ambiguous for those with multiple cancers, unless the tumor inclusion criteria are understood. Depending on the application, different inclusion criteria may be appropriate. This table provides three different methods of tumor inclusion:

^c (c) First invasive tumor ever

^d (d) First invasive tumor for each cancer site diagnosed during the previous 33 years (1975-2007)

^e (e) First invasive tumor for each cancer site diagnosed during the previous 5 years (2003-2007)

For definitions (d) and (e) all sites is treated as a separate cancer "site".

Consider a woman who had three invasive cancers: Melanoma in 1981; Breast cancer in 2003; Melanoma in 2004.

In method (c) the melanoma is the woman's first cancer, and is counted for the melanoma and all sites 33-year limited duration prevalence. For 5-year limited duration prevalence, the woman is not counted at all since her first cancer occurred more than 5 years prior to 1/1/2008. In method (d) the 1981 melanoma is counted for the melanoma and all sites 33-year limited duration prevalence. The 2003 breast cancer is counted for the breast 5-year and 33-year limited duration prevalence.

In method (e) the 2003 breast cancer is counted for the breast cancer and all sites 5-year limited duration prevalence. The 2004 melanoma is counted for 5-year limited duration prevalence for melanoma.